Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from
View Patent ↗A drug delivery system that includes a hydrogel formed from cyclodextrin and an amphiphilic copolymer that includes an A polymer block comprising a poly(alkylene oxide) and a B polymer block comprising a poly(hydroxyalkanoate), and a therapeutically effective amount of at least one therapeutic agent intimately contained within the hydrogel. In one preferred embodiment of the invention, the A polymer block is poly(ethylene oxide) (PEO) and the B polymer block is poly[(R)-3-hydroxybutyrate] (PHB), and the copolymer is the triblock ABA copolymer PEO-PHB-PEO. A method of synthesizing the amphiphilic triblock copolymer is also provided.
1. A drug delivery system, comprising:
a hydrogel formed from an inclusion complex comprising cyclodextrin and an amphiphilic copolymer, wherein the copolymer includes an A polymer block comprising a poly(alkylene oxide) and a B polymer block comprising a poly(hydroxyalkanoate), wherein the poly(alkylene oxide) A block polymer is selected from the group consisting of poly(ethylene oxide), poly(tetramethylene oxide) and poly(tetrahydrofuran) and the poly(hydroxyalkanoate) B block polymer is selected from the group consisting of poly[(R)-3-hydroxybutyrate], poly[(R)-4-hydroxybutyrate], poly[(R)-3-hydroxyvalerate], poly[(R)-3-hydroxybutyrate]-co-Poly[(R)-3-hydroxyvalerate], poly[(R)-3-hydroxyhexanoate], Poly[(R)-3-hydroxyheptanoate], (S) enantiomers of each of such (R) enantiomers, racemic mixtures of such (S) and (R) enantiomers, and mixtures thereof; and
a therapeutically effective amount of at least one therapeutic agent intimately contained within the hydrogel, wherein the copolymer is an amphiphilic triblock copolymer including a B polymer block mid-segment and two A polymer block end segments.
2. The system of claim 1 , wherein the poly(alkylene oxide) A block polymer is poly(ethylene oxide).
3. A hydrogel comprising cyclodextrin and an amphiphilic copolymer in the form of an inclusion complex, wherein the copolymer includes an A polymer block comprising a poly(alkylene oxide) and a B polymer block comprising a poly(hydroxyalkanoate), wherein the copolymer is an amphiphilic triblock copolymer including a B polymer block mid-segment and two A polymer block end segments, wherein the poly(alkylene oxide) A block polymer is selected from the group consisting of poly(ethylene oxide), poly(tetramethylene oxide) and poly(tetrahydrofuran) and the poly(hydroxyalkanoate) B block polymer is selected from the group consisting of poly[(R)-3-hydroxybutyrate], poly[(R)-4-hydroxybutyrate], poly[(R)-3-hydroxyvalerate], poly[(R)-3-hydroxybutyrate]-co-Poly[(R)-3-hydroxyvalerate], poly[(R)-3-hydroxyhexanoate], Poly[(R)-3-hydroxyheptanoate], (S) enantiomers of each of such (R) enantiomers, racemic mixtures of such (S) and (R) enantiomers, and mixtures thereof.
4. The drug delivery system of claim 1 , wherein the copolymer has a molecular weight of between 1,000 and 50,000.
5. The drug delivery system of claim 1 , wherein the copolymer has a molecular weight of between 5,000 and 35,000.
6. The drug delivery system of claim 1 , wherein the at least one therapeutic agent is selected from the group consisting of peptides, proteins, small molecules, genes, antigens, antibodies and fragments thereof and human recombinant proteins, DNA, RNA and DNA nanoparticles.
7. The drug delivery system of claim 1 , wherein the at least one therapeutic agent is in a macromolecular form.
8. The drug delivery system of claim 1 , wherein the at least one therapeutic agent is selected from the group consisting of analgesics, anesthetics, anti-arthritic drugs, disease modifying anti-rheumatic drugs, anti-asthma drugs, anticoagulants, anticonvulsants, antidepressants, antidiabetics, antineoplastics, antipsychotics, antihypertensives, antibiotics, antihistamines, decongestants, anti-inflammatories, muscle relaxants, anti-parasitic drugs, antiviral drugs, anti-restenotic agents, anti-spasm agents, chondroprotective agents, anti-adhesion agents, anti-tumor cell invasion agents, vasorelaxants, vasoconstrictors and immunosupressants.
9. The drug delivery system of claim 1 , wherein the at least one therapeutic agent is selected from the group consisting of peptides, proteins including cytokines, growth factors, angiogenesis factors, soluble receptors, antibodies and fragments thereof and human recombinant proteins, small molecules, genes, antigens including vaccines, DNA, RNA and DNA nanoparticles.